Christina Poh

7PUBLICATIONS
33CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Cancer therapy (excl. chemotherapy and radiation therapy)Haematological tumoursClinical pharmacology and therapeuticsTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Aug 14, 2026
Mosunetuzumab With Response-Adapted Polatuzumab Vedotin and Obinutuzumab in Untreated Indolent B-Cell Non-Hodgkin Lymphoma.

|Mar 19, 2026
Real-world evidence for pembrolizumab gemcitabine vinorelbine and liposomal doxorubicin in classical Hodgkin lymphoma.

Grace Baek, Gaurav Varma, Samuel Yamshon

|Feb 24, 2026
A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis.

Joseph M Tuscano, Tamer Othman, Paul Frankel

|Feb 16, 2026
Pembrolizumab and pralatrexate for relapsed or refractory peripheral T-cell lymphomas.

Christina Poh, Jasmine Zain, James Godfrey

|Nov 10, 2025
A phase 1 study of blinatumomab/lenalidomide in relapsed/refractory B-cell lymphoma: toxicity, efficacy, and correlative analysis.

Joseph M Tuscano, Tamer Othman, Paul Frankel

|Sep 11, 2025
Impact of immunophenotype on clinical disease characteristics and outcomes in T-cell prolymphocytic leukaemia.

Christina Poh, Xueyan Chen, Jenna Voutsinas

Pageof 2

Frequent Collaborators

3 joint publications

Ryan C Lynch

2 joint publications

Chaitra S Ujjani

2 joint publications

Samantha Herbert

2 joint publications

Alexander A Merleev